Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-Abdominal Infection
Conditions
Complicated Intra-Abdominal Infection
Trial Timeline
Apr 3, 2018 → Mar 16, 2020
NCT ID
NCT03217136About Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole is a phase 2 stage product being developed by Merck for Complicated Intra-Abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03217136. Target conditions include Complicated Intra-Abdominal Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03217136 | Phase 2 | Completed |
Competing Products
20 competing products in Complicated Intra-Abdominal Infection